About AngioSafe
Developing a pipeline of novel devices to improve safety and efficacy of complex cardiovascular interventions.
- Industry
- Medical Device
- Company size
- 51-200 employees
- Headquarters
- San Jose, California
- Founded
- 2014
- Company type
- Privately Held
- Company profile name
- AngioSafe, Inc.
AngioSafe® is redefining revascularization through the development of technologies that safely, efficiently, and predictably empower interventionalists to tackle complex lesions. Its proprietary Atheroplasty™ core technology platform does not require any capital equipment and simultaneously combines mechanisms and features to revascularize severely occluded arteries, simplifying one of the most complex procedures in cardiovascular interventions.
With its flagship Santreva™-ATK endovascular revascularization catheter, AngioSafe is advancing a new era of vascular innovation to improve procedure outcomes and confidence for physicians addressing complex femoropopliteal interventions.
Santreva-ATK is FDA cleared and CE marked and is now commercially available.
Specialties
- Peripheral artery disease
- Coronary artery disease
- Complex algorithms
- Catheters
- Safety
- Efficacy
- Design Engineering
- Test Engineering
- Clinical Sciences
- Nonclinical
- Manufacturing
- Quality
- Regulatory
- Quality Engineering
- Marketing
- Commercial
- Medical Affairs
- and Critical Limb Ischemia
Company locations
5215 Hellyer Ave, 240, San Jose, California 95138, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 4,756
- People linked to this company
- 44
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.